Emend® (aprepitant) 165mg Single Dose Oral capsule is set to become the sole aprepitant in use since the removal of Emend® 125mg plus 2 x 80mg capsules tripack from the PBS in December 2013.
Aprepitant 165mg capsule should be administered one hour prior to the initiation of highly and moderately emetogenic chemotherapies, combined with a corticosteroid and a 5-HT3 antagonist, to prevent acute and delayed nausea and vomiting. It is not administered on days two and three.
Elimination is primarily through metabolism by CYP3A4, and therefore as it is a CYP3A4 substrate then concomitant use with CYP3A4 inhibitors (such as rifampicin, St. John’s Wort and some anticonvulsants) may decrease plasma levels of aprepitant and hence result in its decreased efficacy. Emend should not be administered concurrently with pimozide, astemizole, cisapride, or terfenadine.
Adverse effects include; hiccups, asthenia, fatigue, somnolence, headache, dizziness, anxiety, anorexia, GI upset, raised LFTs, dysuria, anaemia, febrile neutropenia, hot flush, anaphylaxis, and Stevens-Johnson syndrome/toxic epidermal necrolysis.
Please review full product information before prescribing.